Rosiglitazone influences the expression of leukocyte adhesion molecules and CD14 receptor in type 2 diabetes mellitus patients

Title:

Rosiglitazone influences the expression of leukocyte adhesion molecules and CD14 receptor in type 2 diabetes mellitus patients

Creator:

Tomáš Štulc, Svobodová, H., Krupičková, Z., Radka Doležalová, Iuri Marinov, and Richard Češka

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:2ecc1591-2156-4209-b1bc-444a89646214
uuid:2ecc1591-2156-4209-b1bc-444a89646214
issn:0862-8408

Subject:

Fyziologie člověka a srovnávací fyziologie, diabetes mellitus, rosiglitazone, cell adhesion molecules, lipopolysaccharide receptor, leukocytes, 14, and 612

Type:

article, články, model:article, and TEXT

Format:

print, bez média, and svazek

Description:

Diabetes mellitus is associated with increased inflammatory response, which may contribute to atherosclerosis progression. Experimental results demonstrated anti-inflammatory activity of glitazones; their effect on leukocyte adhesion molecules has not been studied to date. We therefore studied the effect of rosiglitazone treatment on leukocyte surface expression of adhesion molecules in patients with type 2 diabetes mellitus and compared our results with findings in healthy subjects. 33 subjects with type 2 diabetes and 32 healthy controls were included; patients were examined at baseline and after 5 months of rosiglitazone treatment (4 mg /d). Leukocyte expression of adhesion molecules LFA-1, CD 18 and ICAM-1 was quantified using flow cytometry; in addition, CD14 (lipopolysaccharide receptor) expression was analyzed as a marker of nonspecific immunity. The expression of examined molecules at baseline was higher in patients compared to controls. Despite only mild decrease in blood glucose, ro siglitazone treatment induced substantial decrease of CD18 and CD14 expression and borderline decrease of LFA-1 and ICAM-1 expression (on monocytes only). We thus observed improvement in the expression of leukocyte inflammatory markers after rosiglitazone treatment. This effect is supposed to be mediated by direct effect of rosiglitazone on PPAR- γ receptors on leukocytes., T. Štulc, H. Svobodová, Z. Krupičková, R. Doležalová, I. Marinov, R. Češka., and Obsahuje bibliografii

Language:

English

Rights:

http://creativecommons.org/licenses/by-nc-sa/4.0/
policy:public

Source:

Physiological research | 2014 Volume:63 | Number:Suppl 2

Harvested from:

CDK

Metadata only:

false